- Home
- EQR vs GH Comparison
EQR vs GH Comparison
Compare EQR & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQR | GH |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.5B | 20.6B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | EQR | GH |
|---|---|---|
| Price | $67.93 | $147.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 19 |
| Target Price | $69.63 | ★ $119.79 |
| AVG Volume (30 Days) | 2.4M | ★ 2.5M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | ★ 8.09 | 6.74 |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $2,701,075,000.00 | $982,021,000.00 |
| Revenue This Year | $4.07 | $33.30 |
| Revenue Next Year | $3.14 | $28.27 |
| P/E Ratio | $284.50 | ★ N/A |
| Revenue Growth | 4.76 | ★ 32.88 |
| 52 Week Low | $57.57 | $40.36 |
| 52 Week High | $71.50 | $174.08 |
Technical Indicators
Market Signals| Indicator | EQR | GH |
|---|---|---|
| Relative Strength Index (RSI) | 49.16 | 49.64 |
| Support Level | $58.62 | $94.02 |
| Resistance Level | $69.03 | $174.08 |
| Average True Range (ATR) | 1.24 | 7.41 |
| MACD | -0.22 | -2.85 |
| Stochastic Oscillator | 11.57 | 13.68 |
Price Performance
Historical ComparisonAbout EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 312 apartment communities with over 85,000 units and is developing two additional properties with 665 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.